Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Redona Therapeutics

Request full access

Small molecules that can modulate levels of mirnas by targeting proteins that interact with these mirnas

Cambridge, United StatesFounded 2016Biotech & Life Sciences

About Redona Therapeutics

Redona Therapeutics, formerly known as Twentyeight-Seven Therapeutics, is a clinical-stage biotechnology company founded in 2016. The firm is headquartered in Watertown, Massachusetts, and operates within the drug discovery and biotechnology industries. The company was established by a team of prominent scientists with deep expertise in RNA biology and cancer: George Daley, Richard Gregory, Frank Slack, and Piotr Sliz. The leadership team includes President and CEO Kazumi Shiosaki, a seasoned executive with a history of co-founding and leading successful biotech startups like Mitobridge and Epizyme. Shiosaki's experience, which includes a Ph.D. in Synthetic Chemistry from UC Berkeley and roles at Millennium Pharmaceuticals and MPM Capital, is central to the company's strategy of exploring novel areas of biology.

Redona's core business revolves around developing small-molecule drugs that target enzymes responsible for regulating RNA and DNA processes. The company's scientific premise is that the dysregulation of these fundamental cellular mechanisms, such as RNA splicing, stability, and sensing, is a key driver of serious human diseases, including cancer and autoimmune disorders. By creating therapies that modulate these RNA modulating proteins (RMPs), Redona aims to control the expression of oncogenes and other critical disease-related proteins, thereby restoring normal cellular function. This approach is designed to impact multiple hallmarks of a disease simultaneously, offering a potential advantage over therapies that target a single pathway.

The company's revenue model is based on the development and potential commercialization of its therapeutic pipeline, as well as establishing partnerships to explore applications of its technology outside of its primary focus areas. Redona has successfully raised significant capital to fund its research and development efforts, securing a total of $144 million over five funding rounds, including a notable $65 million Series A in 2018. Its investor syndicate includes major players in the life sciences venture capital space, such as MPM Capital, Sofinnova Partners, Novartis Venture Fund, and Johnson & Johnson Innovation. Redona's pipeline includes several programs targeting enzymes like TUT4/7, cGAS, and CLK, which are implicated in various solid tumors and heme malignancies. The company has developed potent and selective inhibitors that have shown promising efficacy in preclinical cancer models and is advancing them toward clinical studies.

Source: Dealroom company data

At a glance

Status
Operational
Employees
4
Open positions
None listed
Dealroom signal
29.7/100
Industry
Health
Sub-industry
BioTechnology
Sector
Biotechnology, Spinout, Biotech and Pharma, DT and LS, science-based
Business model
Manufacturing
Client focus
B2B

Funding history

9 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
DEBTDebt Aug 2023 $12M — Undisclosed ↗
SERIES AOther financing May 2019 $15M $60M Sofinnova Partners · Vertex Holdings · MPM BioImpact · Novartis Venture Fund —
Showing the latest 2 of 9 recorded eventsBook a demo for the full funding history →

Growth signals

Redona Therapeutics website traffic

Latest recorded traffic for Redona Therapeutics is 4.7K monthly website visits, up 46900% over the last three months. Redona Therapeutics's team grew 0% over the past year.

Latest monthly visits4.7K 3-month web change+46900% 1-year team growth0%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Redona Therapeutics in the Cambridge ecosystem

Live from Dealroom

The Redona Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

10 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A9 investors entered at this stage

Other known investors1 additional known investor

  • Harvard University
Team profiled 3 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators Hidden — book a demo quality score
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
1 countries with
team presence
🇺🇸 United States100%
1 country shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Redona Therapeutics on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Redona Therapeutics’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.